Ophthalmologists have been waiting nearly 20 years for new molecules with novel mechanisms of action (MOA) to treat glaucoma. That long drought could be over by the end of 2016.
“As a clinician, I am hungry for another alternative to treat glaucoma,” said Eydie Miller-Ellis, MD, professor of clinical ophthalmology and director of glaucoma services at Scheie Eye Institute/University of Pennsylvania, Philadelphia. “Hardly a day goes by that a patient doesn’t ask me what’s new, what’s next, isn’t there anything else you can do for me? The day appears to be coming when I will be able to tell them ‘yes,’ there is something new.”
Dr. Miller-Ellis made that optimistic prediction as she introduced two companies moving toward their initial NDA submissions during the “New Horizons in Glaucoma Pharmaceuticals” session. Aerie Pharmaceuticals expects to file its first NDA in mid-2016. Valeant/Bausch + Lomb plans an NDA submission during the second quarter of 2015.
“With a plethora of generic therapeutics, the need for novel MOAs that can perform against the escalating co-pays and controls over access to show that these drugs mean something to patients in terms of their vision is very challenging place to be,” said Paul Chaney, president and CEO of PanOptica. “These two companies are getting closer.”
Chaney co-moderated the session with Dr. Miller-Ellis.